Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600075 | 0.87 | CNR2 (0.72) | KDM4ECNR1CNR2ALDH1A1HPGD | |
| SCHEMBL29629313 | 0.84 | HPGD (0.65) | KDM4EPTGER4ALDH1A1HPGDMAPT | |
| SCHEMBL8922345 | 0.84 | HPGD (0.65) | KDM4EPTGER4ALDH1A1HPGDMAPT | |
| SCHEMBL29629312 | 0.84 | HPGD (0.65) | KDM4EPTGER4ALDH1A1HPGDMAPT | |
| Hydrochloric Acid SCHEMBL8920877 | 0.83 | HPGD (0.63) | KDM4EPTGER4ALDH1A1HPGDMAPT | |
| SCHEMBL602524 | 0.81 | CNR2 (0.56) | CNR1CNR2PTGER4ALDH1A1HPGD | |
| SCHEMBL9459043 | 0.81 | PTGER4 (0.55) | KDM4ECNR2PTGER4ALDH1A1HPGD | |
| SCHEMBL2734561 | 0.80 | ALDH1A1 (0.78) | KDM4ECNR2PTGER4ALDH1A1HPGD | |
| SCHEMBL28266250 | 0.80 | RORC (0.59) | KDM4EPTGER4ALDH1A1HPGDMAPT | |
| SCHEMBL16120149 | 0.80 | CNR2 (0.61) | KDM4ECNR1CNR2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2022-12-01 | — | — | US | disclosed |
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2022-12-01 | — | — | US | disclosed |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | UNIVERSITY OF WASHINGTON (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210094949-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2021-04-01 | — | — | US | disclosed |
| US-20210094949-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, TUBA1C | KDM4E 3152/4885CNR1 2023/4885CNR2 2189/4885 |
| US-20210094949-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, TUBA1C | KDM4E 3152/4885CNR1 2023/4885CNR2 2189/4885 |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | TUBB3, TUBB1, TUBA1C | KDM4E 3152/4885CNR1 2023/4885CNR2 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.